Radiomics to evaluate interlesion heterogeneity and to predict lesion response and patient outcomes using a validated signature of CD8 cells in advanced melanoma patients treated with anti-PD1 immunotherapy.

9 In their study, although the radiomic biomarker on 303 lesions from the 70 patients of the test set reached significant predictive performance (0.66 AUC, p<0.01), only a trend toward significance was obtained from the nodal metastases in melanoma patients (AUC=0.64, p=0.05), and application of the signature was not significant for pulmonary and hepatic melanoma lesions (AUC=0.55).

also in 3,729 other papers